Tissue repair research
TB-500 Research review
Why a trial of thymosin beta-4 eye drops cannot validate injectable TB-500 recovery claims.
Related-molecule trialSources checked September 12, 2026
01 / Context first
The research setting
Adults with dry eye received a thymosin beta-4 ophthalmic formulation, not injectable TB-500.
02 / The findings
What the sources found
- The selected trial missed its primary endpoints; some secondary outcomes improved.
03 / The open questions
Where the evidence stops
- The tested formulation, route, and condition differ from TB-500 injury-recovery claims.
- FDA identifies TB-500 as a thymosin beta-4 fragment; it should not be treated as interchangeable with the trial product.
04 / Safety context
Before drawing conclusions
FDA describes immune-response and impurity concerns and missing human exposure information for the TB-500 fragment.
These reviews do not provide instructions for self-treatment. Discuss personal medical questions with a qualified clinician.
05 / Go to the originals
Read the sources
Inspect the original research and regulatory context behind this review.
- Original research — PubMed abstractThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. ↗
- FDA safety informationCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗
Sources checked September 12, 2026. Next editorial review due December 11, 2026.
Read the review methodology →